KRAS and Patent ductus arteriosus: Although water-insoluble, in mice Mycro3 was amenable to daily administration by oral gavage as an emulsion for treatment of oncogenic KRAS (KRAS*)-induced pancreatic ductal adenocarcinoma (PDA), which is dependent on Myc activity.